What are the benefits of targeted treatment versus surveillance for Stage IIIC, high-grade serous ovarian cancer (HGSOC), BRCA-negative, HRD-negative, after complete gross resection and neoadjuvant chemotherapy, with a CA125 of 32?
This is a really important question, and the honest answer is that your specific profile — Show Full Answer
What are the benefits of targeted treatment versus surveillance for Stage IIIC, high-grade serous ovarian cancer (HGSOC), BRCA-negative, HRD-negative, after complete gross resection and neoadjuvant chemotherapy, with a CA125 of 32?
This is a really important question, and the honest answer is that your specific profile — BRCA-negative and HRD-negative — does make the targeted therapy decision more nuanced than for someone with those mutations. Here's a breakdown of what's currently known:
Targeted Therapy (Maintenance) Options
Even without BRCA or HRD mutations, there are still some options worth discussing with your oncologist:
- Bevacizumab (Avastin) — This is an angiogenesis inhibitor that cuts off blood supply to tumors. It doesn't require a BRCA or HRD mutation and can be used as maintenance therapy after chemotherapy in advanced ovarian cancer
- Niraparib (Zejula) — This PARP inhibitor is unique in that it *does not require a biomarker*, meaning it could still be considered even without BRCA/HRD positivity, though its benefit in HRD-negative patients is more limited The Case for Targeted Maintenance Therapy
- Stage IIIC HGSOC has a high relapse rate, often within three years, even after complete gross resection
- Maintenance therapy aims to delay or prevent that recurrence
- A CA125 of 32 is encouraging, but maintenance therapy is typically considered *before* recurrence, not after
- Bevacizumab in particular has shown benefit in advanced-stage ovarian cancer as a maintenance treatment The Case for Surveillance
- Without BRCA or HRD positivity, the proven benefit of PARP inhibitors is significantly reduced
- Targeted therapies come with side effects, including fatigue, high blood pressure, headaches, nausea, and increased bleeding risk
- Some PARP inhibitor therapies have actually been phased out in recent years as evidence evolved
- Close monitoring with CA125 and imaging may be a reasonable path, especially given the complete gross resection The Bottom Line
Given the HRD-negative status, bevacizumab maintenance may be the most relevant targeted option to explore. It's worth asking your oncologist specifically about biomarker testing results and whether bevacizumab maintenance fits your situation.
This is genuinely a conversation where your oncologist's guidance is critical — the decision really hinges on weighing the side effect burden against the recurrence risk for your specific profile. You're asking exactly the right questions.
September 13
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
